Journal of Nutrition and Metabolism

Journal of Nutrition and Metabolism / 2018 / Article

Review Article | Open Access

Volume 2018 |Article ID 7195760 | 13 pages |

Potential Synergies of β-Hydroxybutyrate and Butyrate on the Modulation of Metabolism, Inflammation, Cognition, and General Health

Academic Editor: Michael B. Zemel
Received06 Dec 2017
Revised06 Feb 2018
Accepted28 Feb 2018
Published01 Apr 2018


The low-carbohydrate high-fat diet (LCHFD), also known as the ketogenic diet, has cycled in and out of popularity for decades as a therapeutic program to treat metabolic syndrome, weight mismanagement, and drug-resistant disorders as complex as epilepsy, cancer, dementia, and depression. Despite the benefits of this diet, health care professionals still question its safety due to the elevated serum ketones it induces and the limited dietary fiber. To compound the controversy, patient compliance with the program is poor due to the restrictive nature of the diet and symptoms related to energy deficit and gastrointestinal adversity during the introductory and energy substrate transition phase of the diet. The studies presented here demonstrate safety and efficacy of the diet including the scientific support and rationale for the administration of exogenous ketone bodies and ketone sources as a complement to the restrictive dietary protocol or as an alternative to the diet. This review also highlights the synergy provided by exogenous ketone, β-hydroxybutyrate (BHB), accompanied by the short chain fatty acid, butyrate (BA) in the context of cellular and physiological outcomes. More work is needed to unveil the molecular mechanisms by which this program provides health benefits.

1. Introduction

Many of our cells can use fat in the absence of glucose to eventually generate energy (ATP) from the fatty acid. However, the brain cannot receive oxidizable fats, as an energy source, as they cannot readily cross the blood-brain-barrier. The water soluble, lower molecular weight ketone can cross and provide neurons with a very efficient energy source [1, 2]. Neurons can thrive with ketones as a fuel source; and some believe this to be a superior energy source especially for individuals with genetic predispositions or lifestyle induced disease related to impaired glucose metabolism [3], including cognitive deficits [4, 5].

Dietary fat is said to have played a critical role in the evolution of the human brain since the brain needs a dense calorie load to sustain it energetically but also needs the fat building blocks to support its development [6]. This dogma certainly continues today based on research that shows that docosahexaenoic acid (DHA) and other fats play a crucial role in neural tissue growth and function. Anomalies in fat metabolism or shortfalls in dietary fats can interfere with brain development and function [7]. In fact, experts assert that a move away from the higher fat diet might be more the cause of the North American metabolic syndrome epidemic.

Statistical review of US macronutrient consumption today reveals an increase in the incidence of obesity correlating with the reduction in dietary fat; which results consequently in increased intake of carbohydrate foods [8]. Somewhere in the middle closer to the low carbohydrate end of the diet is a happy healthy medium where processed carbohydrate sources are limited and healthy fat is loaded but a good supply of fresh vegetables (low glycemic index carbohydrate sources) still comprises a significant component of the diet [9]. In particular, it is speculated that a lower overall intake of carbohydrate sources is the healthier way to go with these choices making up, for the major part, those of a lower glycemic load and higher fiber constitution.

It is well understood that dietary restriction in the form of calorie or carbohydrate deprivation is conducive to ketogenesis and serum ketone elevation [10]. The low-carbohydrate high-fat diet (LCHFD) has cycled in and out of popularity for decades as a therapeutic program to treat metabolic syndrome [11]; epilepsy [12]; cognitive deficit [13]; neurological disorders like Alzheimer’s disease where its shown to downregulate deleterious amyloid protein [14]; as an activator of uncoupling protein activity for thermogenesis [15]; and weight loss [16]. The ketogenic diet is far from a novel concept. The understanding that this dietary protocol can effectively reduce seizure frequency [17] and help treat even drug-resistant epilepsy [18] was established as far back as the 1920’s [19, 20].

This review highlights the benefit of the ketogenic or low-carbohydrate high-fat diet and provides compelling evidence of its safety and efficacy. Scientific support and rationale are also presented for the administration of exogenous ketone body and other ketone sources of varying types as a complement to the restrictive dietary protocol or as an alternative to the diet. We recommended a specific protocol that involves the administration of an exogenous ketone, β-hydroxybutyrate (BHB), accompanied by the short chain fatty acid, butyrate (BA). This review highlights the synergy provided by this combination of BHB-BA in the context of cell signaling and inflammatory control and its use as a substrate for ATP generation through the TCA cycle.

2. What Is a Ketogenic Diet?

The ketogenic diet is represented by a distinct macronutrient profile: 65–70% fat; 20% protein; and 5–10% carbohydrate. A daily carbohydrate intake that does not exceed 75 grams on average is needed in order to stay in ketosis; a 50 gram maximum is preferred. One cup of cooked rice, for example, will topple the ketogenic state with a 50 gram carbohydrate count, as can a large apple or banana for many with a count as high as 40 grams for each. The protein type selected in the diet can also have a major influence on serum glucose status. Leucine, a ketogenic amino acid that is often abundant in a typical diet can have a significant influence in support of the ketogenic initiative, on insulin sensitivity and serum glucose clearance [21]. Other amino acids such as alanine, cysteine, and glycine are highly gluconeogenic and during starvation or energy deprivation can be readily converted to glucose by the body [22]. Gluconeogenic/glucogenic amino acids also include arginine, serine, and proline. Eaten abundantly as in a protein source, these amino acids can counter the ketogenic initiative.

Although there are significant health benefits associated with moderate hyperketonemia whether used for therapy or simply life quality improvement, this state is not easy to attain and maintain without significant planning and dietary sacrifice [23, 24]. In fact, the ketogenic lifestyle is very difficult to maintain today for most of the world’s population considering our carb-centered cultures. Carbohydrate sources are also hidden in many processed foods. The controversy generated by the medical community related to ketoacidosis risks just helps the layman public make a choice down the path of least resistance—along the carb-laden course. Nevertheless, nutritional ketosis is very different from ketoacidosis. Ketosis induced by dietary modifications that limit carbohydrate intake (or reduce total calories) and elevate healthy fat intake is very different from that of pathological ketoacidosis associated with type-1 diabetes and related diabetic conditions [25, 26]. Safe hyperketonemia can reach levels as high as 10 mM with extended periods of fasting or persistence with the ketogenic diet [27, 28]. Nevertheless, ketosis tends to be regulated at that point by feedback mechanisms [29]. Ketoacidosis is more characterized by serum ketone levels in excess of 18 mM [30].Why a ketogenic lifestyle?

We have become desensitized to the fact that serum glucose, itself, is very toxic to the body when uncontrolled, and we fail to appreciate the parallels with serum ketone bodies. When serum glucose is mismanaged, the resulting advanced glycosylated end products (AGEs) [31, 32] and inflammation [33, 34] pose significant toxicity [35] and risk of morbidity [36]. AGE-modified LDL (low-density lipoprotein) is a driver of atherosclerosis and other cardiovascular diseases [37]. The body’s response to a diet that persists to deliver high glycemic index foods is not health promoting. A basic understanding of endocrine physiology tells us that every time we spike insulin due to intake of high glycemic index carbohydrate foods, lipolysis is inhibited and energy substrates are shuttled to storage including to fat cells cells [38]. This activity is conducive to adipose fat accumulation and reduces the potential for fatty acid oxidation as an energy substrate in the sedentary or work-loaded situation.

Serum ketone uptake by cells occurs through pathways independent of insulin [39]. Therefore, as much as insulin resistance can impair glucose availability to insulin dependent cells, the ketone can be utilised as an energy substrate despite the insulin dysfunction. Additionally, evidence shows that elevated serum ketone bodies suppress hepatic glucose output and by this mechanism also help mitigate elevated serum glucose [40]. The ketogenic diet is certainly antidiabetic for the type 2 diabetic patient and can play a role in treatment [41].

What the research indicates is becoming well accepted; carbohydrate restriction can contribute significantly to improvement in weight management [42, 43], enhanced serum glucose management in prediabetic and diabetic patients [44], and even reduced frequency of insulin requirement in cases of insulin dependent diabetic conditions [45, 46]. Carbohydrate restriction is not the only dietary strategy that combats lifestyle-related morbidity.

As beneficial as it can be for weight management and correction of metabolic syndrome, calorie restriction by carbohydrate restriction is notoriously poorly tolerated unless coupled to a compensatory higher fat intake which contributes to an equicaloric outcome [47]. The LCHF diet contributes to down-shifts in serum glucose including fasting serum glucose and glucose tolerance [48]. If the carbohydrate intake is low enough, serum ketone levels can rise to support energy demands and health in multiple profound ways that research is showing to be convincing [49, 50]. Still, poor tolerability of the low-carbohydrate diet is a challenge leading to lack of compliance, and a pill, for too many of us, seems to be an easier solution.

3. Endogenous Ketone Generation

The liver is the primary site of fatty acid β-oxidation from serum-derived fatty acids for the generation of ketones that can subsequently serve as energy substrates for the brain [5153]. In a healthy individual with intact pancreatic β-cell function and insulin feedback, serum ketone levels are managed spontaneously [54]. Serum ketones, acetoacetate and acetone, as well as the ketone body β-hydroxybutyrate, serve as signaling ligands that downregulate hepatic β-oxidation of fat [55] to regulate serum load. There is compelling evidence that goes back decades supporting the existence and efficacy of this feedback system and the meticulous regulation of ketone synthesis at the transcriptional level [27].

How does the serum ketone story relate to the serum glucose model? The story is analogous. In both models, poorly regulated levels of the energy substrate can lead to toxicity, but levels that are spontaneously managed by the healthy physiology are supportive of healthy metabolic performance. In fact, the healthy window for serum glucose is not much different from that of the healthy window for serum ketones. A healthy window for serum ketones in the context of hyperketonemia is documented to be 2.0 mM to 8.0 mM serum ketones [56]. This range is considered mild to moderate hyperketonemia produced as a survival mechanism during prolonged periods of starvation [25, 53]. Basal levels for most healthy individuals range from 0.1 mM to 0.2 mM serum ketone [57]. Serum ketones are readily used as energy substrates if glucose is scarce [58] in most tissues of the body including the heart [59] and brain.

Nevertheless, this restrictive diet can be made more tolerable with the administration of exogenous ketone supplementation that offsets the lag and energy drag associated with delayed endogenous ketone production and serum elevation [60, 61]. Upon initialisation of the ketogenic diet, it can take as long as five days to reach serum ketone levels that can meet ATP demands as an alternative substrate to glucose. These transition days can prove to be difficult leading to cheat days; while maintenance of functional serum ketone levels also depends on adherence to the diet [62, 63]. This exogenous ketone supplement, as opposed to other diabetic drugs, may be the support needed to make the ketogenic diet tolerable.

Alternatively, cheating while on the ketogenic diet simply slows metabolic transition to the ketone serving as a primary energy substrate. At about the third day of glucose deprivation, the brain begins escalating its dependence on ketones as an energy substrate, and by 96 hours, the brain can be using ketones for most of its ATP needs [64]. In fact, ketones can serve as ATP substrates to supply as much as 70% of the brain’s energy to meet demand [65, 66]. In cases of dementia, including Alzheimer’s disease, elevated serum ketones (ketosis) are showing promise as a viable treatment [6769], and the underlying mechanism is quite fascinating.

4. Exogenous Ketone Administration

Endogenous ketone generation is a normal and healthy survival mechanism that allows for resilience to prolonged periods of starvation [58]. However, in addition to serving as an ATP substrate, these ketones also serve as ligands that regulate cell signaling and behavior [27]. Nevertheless, these benefits are limited to the level of compliance by the individual on the ketogenic diet, and compliance is poor especially in children. Supplementing with exogenous ketones or ketone bodies might be the answer to the compliance challenge that concurrently contributes to conducive pharmacology. Exogenous supplementation of the ketone or proketone (BHB) by oral route is showing promise and is successfully in use today since 1975. BHB can readily convert back and forth to the other ketone bodies such as acetoacetate and downstream to acetone. Acetone and acetoacetate are biological ketones comprising serum ketone load [70].

The ketogenic diet as a therapy poses challenges because it requires extraordinary dedication and sacrifice, while causing the user to endure states of malaise during energy substrate transition. For some, the achievement of ketosis is more difficult than for others based on metabolic, genetic, environmental, social, cultural, and lifestyle factors combined. Acute supplementation with an exogenous ketone source can serve as a bridging energy substrate to offset the energy deficit associated with this metabolic transition while providing a serum ketone source that additionally serves as a signaling ligand. However, it may also play a role independent of dietary commitments due to its signaling.

The high dosing used in research and current commercial supplement programs could be deemed unnecessary. Consumers are using doses as high as 10 grams per serving of BHB accompanied by medium chain triglyceride (MCT) inclusions that serve as substrates for β-oxidation and BHB generation. The oral MCT load is notoriously associated with gastrointestinal distress including diarrhea in many users [7175]. In addition, these common BHB supplements carry with them a sodium load that can reach 1300 mg sodium per serving. These extremely high-therapeutic doses should be administered with dose-related degrees of monitoring by a health care professional.

5. Benefits of Exogenous Ketone

Therapeutic applications for exogenous ketones and ketone bodies like BHB have merit in multiple disease models. In vivo study of ketone supplementation (BHB) decreased tumor growth and prolonged subject survival independent of other dietary inclusions; including independence from serum glucose levels [76]. BHB is shown to play a role in mediating NLRP3 inflammasome-induced IL-1β and IL-18 in human monocytes [77] to positively influence inflammation. This may play a role in the treatment of autoinflammatory diseases. Therapeutic ketosis supported by an exogenous ketone downregulates seizure onset in epilepsy [78]. BHB also helps improve cardiac health by reducing myocardial glucose uptake and increasing blood flow [79].

In the course of treating brain hypometabolic diseases like Alzheimer’s disease (AD), 10–20 grams daily of exogenous ketone supplementation in divided doses are used with success [80]. AD is associated with compromised glucose metabolism of central nervous system neurons correlating with cognitive deficit [8184]. Since the ketone does not depend on insulin for uptake and can be used by the mitochondria of neurons efficiently, its prevalence can help overcome some of the energy shortfalls in these diseased brains [85]. Serum levels do not have to rise significantly in order for the brain to be served with the alternative substrate, and this could factor into minimising potential risk as in minimising the exogenous dose required for treatment. Hyperketonemia, where systemic plasma ketones increase just beyond common baselines of (0.2 mM) are shown to improve brain ketone status and consequently serve neurons with an alternative energy substrate to glucose [80].

Elevated serum ketones are shown to attenuate apoptosis in neurodegenerative disease by supporting healthier mitochondrial activity and inhibiting apoptotic proteins [65]. Neurodegeneration rising out of toxicity, injury, or ischemia results in oxidative stress. Exogenous ketone administration in murine models safely inhibits generation of reactive oxygen species [86]. The ketogenic diet has been well documented to be an efficacious therapy for the treatment of epilepsy, including drug-resistant epilepsy [87, 88]. However, exogenous ketone administration is also being used to successfully treat nontractable epilepsy [78, 89].

In an experimental model, exogenous ketones have been found to increase athletic as well as cognitive performance in rats [90]. However, the extent to which exogenous ketones can regulate or enhance prolonged endurance type exercise in human still remains unknown [91]. Exogenous ketones and ketone bodies can serve as tremendous health-promoting agents, but as will be further demonstrated, the combination of BHB with its molecularly analogous short chain fatty acid, butyric acid (BA), may serve as a more appropriate technology for most users.

6. Safety of Exogenous Ketones in the Food Supply and in Therapy

Various ketone sources exist naturally in our food supply. Dairy milk contains levels ranging from 10 to 631 M, making dairy products a natural source of β-hydroxybutyrate [92, 93]. The United States FDA classifies various forms of β-hydroxybutyrate as “Generally recognised as safe (GRAS).” Exogenous ketones (or ketone bodies) are safe, but how much is too much?

Human subjects tested an exogenous ketone supply as 395 mg/kg of a ketone ester with and without an accompanying meal to show serum BHB levels one hour after administration. Serum BHB was lower in FED versus EMPTY (2.1 mM ± 0.2 mM versus 3.1 mM ± 0.1 Mm) stomach administration. These extreme doses convert to 31.6 grams ketone ester for an 80 kg (176 lb) person and were well tolerated [94]. Another human trial utilizes an oral dose of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate, a monoester of the BHB molecule, quantified at 714 mg/kg. These doses convert to 57.1 grams ketone ester for an 80 kg (176 lb) person. Maximum plasma ketones were achieved within 2 hours (3.30 mM BHB and 1.19 mM acetoacetate). This high dose was administered for five days three times per day, and it too was tolerated [95]. A typical 8-hour fast can result in 0.5 mM serum ketones [95]. Within a period of seven fasting days, total blood ketone levels can reach 5 to 7 mM [25, 95]. A toxicity study in rats receiving 12 and 15 g/kg weight (females and males resp.) also supports the safety of the β-hydroxybutyrate dosing [96].

Oral sodium D,L-β-hydroxybutyrate (1000 mg/kg body weight per day) has been administered to children as young as two years old with cardiomyopathy and leukodystrophy from acyl-CoA dehydrogenase deficiency. Within one week of starting the treatment, improvement was noticed from complete paralysis to restored neurological function after two years to include walking and improved brain MRI. Two additional children with the same condition unresponsive to typical treatment showed progressive improvement with the same treatment [97]. In infant hyperinsulinemic hypoglycemia, two six month olds were treated and monitored for five and seven months. Four and eight gram doses, respectively, were administered and well tolerated [60]. It should be noted that extreme therapeutic dosing such as these requires medical monitoring.

7. Health Benefits of Butyrate

Short chain fatty acids, also known as volatile fatty acids, are those typically produced by the microbial community of the intestine. These fatty acids include most abundantly, butyrate, propionate, and acetate generated as by-products of dietary fiber fermentation by the gut’s symbiotic microbes [98]. These gut microbes are recognised as pivotal contributors to health in ways that reach beyond even complex immune system support. It’s very clear that commensal bacteria partake in the synthesis of vitamins [99], and they produce an important energy source in the form of the short chain fatty acids [100]. The short chain fatty acids they produce cycle back to regulate and maintain the healthy gut microbe population while altering the luminal environment to void pathogens [101, 102]. Luminal butyrate adversely affects pathogenic bacteria like Escherichia coli, Salmonella spp., and Campylobacter spp. [103].

Nevertheless, butyrate’s reach beyond the colon where it is generated extends to improve insulin sensitivity systemically [102]. Orally consumed butyrate is shown to induce GLP-1 secretion [104], a hormone known to support the improvement of glucose tolerance and appetite control. In the brain, it delivers profound effects the mechanisms of which are not always clear. It is shown to stimulate neurogenesis in the ischemic brain via brain derived neurotrophic factor (BDNF) upregulation [105]. It has antidepressant-like effects [106]. Research shows that butyrate fed mice remain lean (despite dietary calorie load) [107]; have increased energy expenditure in the form of body heat generation; and tend to be more physically active [108, 109].

Butyrate has been shown to have a significant preventive influence on cardiovascular health [110, 111]; reduce serum triglycerides by as much as 50% compared to controls [112]; and lower endogenous cholesterol production [112]. Butyrate and acetate are reported to protect against diet-induced obesity [107, 113]. Butyrate administration has been shown to improve appetite and food portion control [114].

Research has further shown that butyrate is a key fuel for epithelial cells of the intestinal tract and that it may improve gut lining integrity [115]. Similar to BHB, butyrate is an inhibitor of histone deacetylases (HDAC) to induce global changes in genetic transcription of genes encoding oxidative stress resistance [116]. HDAC modulation is also associated with retrieval of long-term memory to recognition [117]. This regulation of gene transcription also results in improved protection from free radical damage associated with strained or extreme metabolic conditions (and environmental toxins). This genetic influence by butyrate administration also includes neuroprotection and improved memory recall in AD models, similar to that exhibited by BHB [118].

Butyrate is shown to inhibit NF-kB and increased I-kB levels as a countermeasure for improved long-term inflammatory control [119]. Oral sodium butyrate attenuates experimentally induced colitis [120]. Orally administered butyrate exerts an anti-inflammatory effect and remission in Crohn’s disease patients through downregulation of NF-kB and IL-1β [121]. Intralumen butyrate has been shown to directly support health of the gastrointestinal lining [103], to exhibit trophic effects on intestinal cell proliferation and improve villi status [122]. In addition, butyrate has been shown to be a potent promoter of intestinal regulatory T-cells [123] establishing yet another immune regulating mechanism that promotes better inflammatory control at the mucosal lining as well as a mechanism for its inhibition of cancer [124].

Butyrate is shown to reduce or inhibit the microbiome population responsible for generating propionic acid [125]. Propionic acid is implicated in Autism Spectrum Disorders (ASD) [126]. It is speculated that butyric acid’s downregulatory influence of propionic acid-producing gut bacteria is the mechanism for improved cognitive status [127]. Interestingly 70% of children with autism or ASD have gastrointestinal disorders and altered gene expression in the brain as a function of the resulting short chain fatty acid imbalance [128].

The list of health benefits associated with the oral administration of butyrate and other short chain fatty acids is vast (Table 1) and conducive to the goal desired with BHB administration. Passive absorption of water in the colon depends on short chain fatty acid availability [129131]. Butyrate has been shown to play a role in healthy peristalsis to help normalize movement in cases of constipation or diarrhea [132, 133]. Butyrate serves to support optimal hydration and optimal bowel elimination function [134]. This pharmacology helps counter the potential adverse events associated with BHB supplementation.

Health benefitsResearch modelReference

Induces GLP-1 secretionIntestinal L cells[104]
Stimulates neurogenesisRat[105]
Antidepressant effectRat[106]
Obesity managementMouse[107, 113]
Better insulin sensitivityMouse[108]
Improves cardiac health with lower cholesterol productionHuman cell line, human[111, 112]
Improves gut lining integrityHuman epithelial cell[115]
Neuroprotection and improved memory recall in Alzheimer’s diseaseMouse[117]
Provides improved long-term inflammatory control, including Crohn’s diseaseMouse, human[120, 121]
Reduces propionic acid-producing microbesRat[126]
Maintains healthy peristalsisHuman[132, 133]
Stimulates fatty acid β-oxidation by inducing FGF21Human[135, 136]

Butyric acid is also abundantly supplied in the diet from dairy sources. In fact, butter is one of the richest butyric acid food sources with a naturally inherent supply of 3-4% of its fat content as butyric acid. One tablespoon of butter typically delivers 14 grams of fat; of which 560 mg is butyric acid. It is easily possible for an individual to consume well in excess of 1000 mg of butyrate in a day from natural sources. However, to do so has an excessive exogenous fat, including an exogenous cholesterol consequence. Nevertheless, for those on carbohydrate-restriction and/or calorie-restrictive diets where dairy, especially butter and creams, might be avoided and fiber could be easily limited, dietary butyric acid intake and synthesis will be compromised. A supplemental source such as that discussed here is of significant value.

Butyrate supplementation also directly compounds the benefits offered by a ketogenic diet and exogenous ketone supplementation in a synergistic way. Butyrate induces FGF21 in serum, liver, and adipocytes, which in turn stimulates fatty acid β-oxidation and hepatic ketone production [135, 136]. This is a central feature of the butyrate pharmacology that directly synergises its activity to the ketogenic goal. It serves as an inducing signal for ketosis to contribute additive activity to a lower oral BHB dosing. Butyrate itself, can serve as a direct substrate to undergo β-oxidation as well [137].

8. The Plausible Benefits of Coupling Butyrate (Short Chain Fatty Acid) with BHB

Butyrate serves as a significant synergistic force for ketosis induction; BHB ligand interactions and pharmacology; and general health, fitness, and performance support. As discussed, an exogenous supply of ketones, such as a BHB salt, will provide an immediate alternative energy (ATP) substrate for the brain during periods of calorie or carbohydrate deprivation. However, concurrent butyrate supplementation in the form of sodium, calcium, or potassium butyrate (or its esters) will prompt the body to induce endogenous ketone synthesis; serve as a ligand to stimulate receptors that the ketone or ketone body will also act on; contribute to the improvement of insulin and general metabolic health; support inflammatory and general immune system health; support neurological health; support gastrointestinal health and integrity; and serve as an energy substrate for ATP generation directly—all in parallel with the benefits that concurrent supplementation of the sister ketone body (BHB) will provide.

The value of this combined system in the context of the ketogenic initiative is sensible. It must be highlighted that the common LCHF diet or ketogenic lifestyle is characterized by compromised carbohydrate intake which consequently results in compromised fiber intake. This ultimately gives rise to a potential deficiency in microbiome health and limitations of the potential short chain fatty acid by-products of the microbiome, including butyric acid. In addition, when we consider the fact that the microbiome is at regular risk of attack by environmental and dietary factors and pharmaceuticals such as antibiotics [138, 139], the supplemental butyric acid in the context described is fitting.

9. Butyric Acid Turns the Ketone into a Potential Weight Loss Strategy

Supplementation with the ketone body, BHB has come under much scrutiny in the context of weight loss claims. This is especially so with MCT accompanied BHB supplements. The ketone will carry with it a caloric contribution as will the medium chain triglyceride. High doses therefore add calories to the daily intake that need to be worked off. In addition, research demonstrates that a rise in serum ketones can inhibit lipolysis, not induce it, so the blanket claims for fat loss by ketone supplementation are not at all appropriate [53, 140]. On the other hand, research does support appetite control and improved body mass proportions with BA supplementation [107, 112114]. BA is also shown to improve markers of cardiovascular health [112]. A careful balance using the ketone as a bridging factor for brain/cognitive health and a signaling ligand beyond that associated with the neuron is a fit in the program. Nevertheless, an activation signal such as that from butyric acid to turn on fatty acid β-oxidation and the ‘burning’ of fat for energy is critical in this context.

Using exogenous BA with an exogenous BHB source may have tremendous value in a prework program where calorie management is also a concern. Leveraging this technology to serve as an efficient energy source for a fasting workout may compound the potential for fatty acid oxidation as an energy substrate. Acute nutritional ketosis is shown in research to reduce lactate production and improve performance (time-trials) potential in some forms of activity (cycling) [141]. It is shown to prevent muscle wasting (catabolism) and protect the brain and other tissues from oxidative activity [142]. It makes sense to apply the combined BHB and BA as a preworkload strategy especially if a fasting workout is the norm.

10. A Closer Look at Subcellular Pharmacology

A number of studies have been reported to map the mechanisms responsible for the pharmacology of the BHB-BA complex in the context of dietary supplements. Research demonstrates that various G-protein-coupled HCA receptors serve as targets for endogenous ketone and ketone body ligands [143]. This receptor family is shown to be classified into multiple subtypes that possess distinct features such as ligand specificity. While BHB serves as an efficient agonist for the HCA2 receptor, for example, it is not able to serve as an agonist for other HCA receptors. Both BA and BHB are signaling ligands for various receptors involved in neuroinflammatory control, including the HCA2 receptor [144].

Other ligands including other ketones can serve as agonists to alternate HCA receptors but they may not be able to trigger a transduction cascade from the HCA2 receptor. HCA receptors can be found in various tissue and cell types including adipose and macrophages [143]. The expression of these receptors can also be induced in immune cells such as macrophages by various cytokines to upregulate the subcellular influence of their ligands. Free fatty acid (FFAR) and HCA receptors could very well be central targets for prevention and treatment of type 2 diabetes, obesity, and inflammation [145]. These fatty acid receptors are emerging targets for the treatment of diabetes regulating cholecystokinin, peptide YY, and leptin, factors intimately involved in the regulation of feeding behavior and nutrient balance. The naturally occurring ligands, BHB and BA, are already effectively modulating these therapeutic targets.

All three HCA receptors are expressed in adipocytes. The HCA1 receptor is activated by hydroxypropanoic acid (lactate), for example, while HCA2’s agonist is BHB, and HCA3 is activated by another β-oxidation intermediate [146]. The regulatory influence by these two natural butyrates on transcription factors involved in transcribing cytokines that regulate inflammatory cascade and immune system activity is expected to be intimately associated with NF-kB modulation.

Nuclear factor erythroid 2-related factor 2 (Nrf2) is the primary transcription factor that is responsible for initiating responses to oxidative stress. Studies showed that the ketogenic diet systematically induces Nrf2 through mild oxidative and electrophilic stress [147, 148]. Nrf2 transcribes a series of endogenous antioxidant defense systems. The transcription factor translocates to nucleus and binds the antioxidant response element (ARE) to transcribe cytoprotective genes [149]. Nrf2 transcribes the endogenous antioxidant peptides hemeoxygenase-1, catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GSH/GPx) [150152] in response to stress as a preservation mechanism. It is more recently being targeted as a chemopreventive target with the intention of stimulating endogenous antioxidant saturation to block the damage by cancer and chemotherapy drugs on healthy host cell DNA [153, 154].

Nrf2 induction or overexpression is shown to heighten cellular defense mechanisms during metabolic stress and convey neuroprotection during toxin-induced mitochondrial stress to the point of reduced lesion development [155, 156]. This cellular protection is also seen in the context of chemotherapy where concurrent Nrf2 induction protects healthy cells [157]. Nrf2 induction protects cells from LPS-induced inflammatory activity and mortality [158]. Nrf2 signaling pathways are showing promise as a counteraction to mitochondrial dysfunction in PD [159]. Nrf2 induction is shown to convey critical defense against elevated serum-glucose-induced oxidative injury to cardiac muscle cells [160].

Interestingly, the diabetic condition is associated with downregulation of Nrf2 activity via ERK, a factor speculated to be a contributor to stress-induced insulin resistance in cardiac cells [161]. Studies show that Nrf2 activation can be used as a therapeutic application to “improve metabolic disorder and relieve renal damage” associated with diabetes [162]. The widespread existence of Nrf2 and its role in cellular protection as a master regulator of antioxidant defense make it a viable target for upregulation against toxicity in most organs and tissues of the body [163, 164].

Hemoxygenase-1 expression, regulated and transcribed by Nrf2, plays an important role in the antioxidant defense mechanism alongside other common endogenous antioxidants to support recovery from injury, toxicity, and hypoxia [165, 166]. Ischemia is a common cause of cell dysfunction and death and is a function of the interruption of blood flow or oxygen availability to tissues resulting in deleterious events. It is known to be central to the pathology of stroke and one of the more common causes of permanent cell and tissue damage in heart disease [167]. Hemeoxygenase-1 induction is highly correlated with protection from ischemia in neurons [168] and heart tissue [169]. Overexpression of glutathione peroxidase is also associated with resistance to myocardial ischemic reperfusion injury [170, 171].

Butyrate has also been shown to activate Nrf2 [172, 173]. The literature already shows signs that treatment with BA or its salts (sodium butyrate) alleviates oxidative stress [174] and will improve catalase activity [175]. Preconditioning with BA administration protects myocardial injury associated with ischemia by inhibiting expression of inflammatory cytokines [174]. It protects the pulmonary artery smooth muscle cells from oxidation associated with hyperoxia [175] and improves metabolism and muscle atrophy associated with aging [176].

11. Future Research

Many can benefit from the state of ketosis associated with these oral strategies including individuals looking to achieve better appetite control, fitness, improved mentation and energy, improved stamina, cellular protection, and other health modifying goals. Based on the metaanalysis of the literature, these goals may also involve relief from inflammation; cognitive deficit associated with neurological disease, trauma, ADD, or others; improved gastrointestinal health; and support of recovery from exercise or intensive performance training. More clinical work is needed before we know more accurately how these strategies can be used reliably.

The BHB-BA coupling appears to facilitate subcellular activity that counters Nrf2 downregulation associated with diabetic or other metabolic conditions that may adversely influence Nrf2 status. The pharmacology of BA is supportive and possibly synergistic. We will be conducting more work to investigate this potential. Although the evidence demonstrating the health benefits of BHB and BA as a combination for oral administration is compelling, the continued research to unveil the mechanisms driving this pharmacology will be of value.

12. Discussion

Based on the current evidence in the literature, the application of the exogenous ketone (body) appears to be a viable strategy supporting tolerance of the ketogenic diet. The administration of BA on its own has been reported to deliver positive results in support of fitness, weight management, cognition, and performance enhancement with or without dietary restriction. The current research initiative in our lab is designed to further investigate the subcellular influence by BHB and BHB-BA on key immune system cells at serum concentrations we are able to achieve as a result of the minimum recommended BHB-BA dose (as high as 1.67 mM serum BHB).

Exogenous BHB-BA supplementation could be a functional strategy that induces β-oxidation and helps raise serum ketone levels indicative of ketosis (>0.2 mmol) with or without having to engage in stringent deprivation of macronutrients and consequential micronutrient limitations. The coadministration of BHB with its related BA molecule could appear to be an efficient way to accomplish this goal using extremely low and safe oral doses. As such, a carbohydrate or calorie-restrictive diet may not be necessary in order for one to benefit from therapeutic value associated with the signaling activity by this exogenous BHB-BA supplementation. However, it is expected that ketogenic dietary practices applied concurrently with the exogenous BHB-BA supplementation will serve the therapeutic objective more effectively especially in the case of cognitive disorders and weight management.

Nevertheless, supplementation with the BHB-BA source will support tolerance of a restrictive dietary protocol; therefore, its application is an especially great fit as a complement to the dietary initiative. A supplement such as this BHB-BA type should be labelled with a common warning statement as such—Consult a physician before use. Do not use if pregnant or breastfeeding. Not recommended for Type I diabetic patients.

Conflicts of Interest

Franco Cavaleri is the owner of a biomedical research group, Biologic Nutrigenomics Health Research Corp., and Biologic Pharmamedical Research that funds and executes research on the pharmacology of nutritional, nutraceutical, and pharmaceutical agents that are studied in the context of disease pathology including characteristics that have been associated with inflammation and dementias. Franco Cavaleri is also the owner of ketone-based and other related intellectual properties. Emran Bashar is an employee of the Biologic Pharmamedical Research.

Authors’ Contributions

Franco Cavaleri was responsible for background research and preparation and editing of the manuscript. Emran Bashar was responsible for conducting research and preparation and editing of the manuscript. Franco Cavaleri and Emran Bashar generated research plans.


  1. A. Gjedde and C. Crone, “Induction processes in blood-brain transfer of ketone bodies during starvation,” American Journal of Physiology–Legacy Content, vol. 229, no. 5, pp. 1165–1169, 1975. View at: Publisher Site | Google Scholar
  2. M. Pollay and F. Alan Stevens, “Starvation-induced changes in transport of ketone bodies across the blood-brain barrier,” Journal of Neuroscience Research, vol. 5, no. 2, pp. 163–172, 1980. View at: Publisher Site | Google Scholar
  3. S. Cunnane, S. Nugent, M. Roy et al., “Brain fuel metabolism, aging, and Alzheimer’s disease,” Nutrition, vol. 27, no. 1, pp. 3–20, 2011. View at: Publisher Site | Google Scholar
  4. M. A. Reger, S. T. Henderson, C. Hale et al., “Effects of β-hydroxybutyrate on cognition in memory-impaired adults,” Neurobiology of Aging, vol. 25, no. 3, pp. 311–314, 2004. View at: Publisher Site | Google Scholar
  5. L. C. Costantini, L. J. Barr, J. L. Vogel, and S. T. Henderson, “Hypometabolism as a therapeutic target in Alzheimer’s disease,” BMC Neuroscience, vol. 9, no. 2, p. S16, 2008. View at: Publisher Site | Google Scholar
  6. W. R. Leonard, “Dietary change was a driving force in human evolution,” Scientific American, vol. 287, no. 6, pp. 106–116, 2002. View at: Publisher Site | Google Scholar
  7. S. M. Innis, “Dietary (n−3) fatty acids and brain development,” Journal of Nutrition, vol. 137, no. 4, pp. 855–859, 2007. View at: Publisher Site | Google Scholar
  8. E. Cohen, M. Cragg, A. Hite, M. Rosenberg, and B. Zhou, “Statistical review of US macronutrient consumption data, 1965–2011: Americans have been following dietary guidelines, coincident with the rise in obesity,” Nutrition, vol. 31, no. 5, pp. 727–732, 2015. View at: Publisher Site | Google Scholar
  9. J. Scholl, “Traditional dietary recommendations for the prevention of cardiovascular disease: do they meet the needs of our patients?” Cholesterol, vol. 2012, pp. 1–9, 2012. View at: Publisher Site | Google Scholar
  10. G. Mullins, C. Hallam, and I. Broom, “Ketosis, ketoacidosis and very-low-calorie diets: putting the record straight,” Nutrition Bulletin, vol. 36, no. 3, pp. 397–402, 2011. View at: Publisher Site | Google Scholar
  11. D. K. Layman and D. A. Walker, “Potential importance of leucine in treatment of obesity and the metabolic syndrome,” Journal of Nutrition, vol. 136, no. 1, pp. 319S–323S, 2006. View at: Publisher Site | Google Scholar
  12. M. Lawson and V. Shaw, “Ketogenic diet for epilepsy,” in Clinical Paediatric Dietetics, pp. 222–232, Blackwell Science Ltd., Oxford, UK, 2nd edition, 2001. View at: Google Scholar
  13. R. Krikorian, M. D. Shidler, K. Dangelo, S. C. Couch, S. C. Benoit, and D. J. Clegg, “Dietary ketosis enhances memory in mild cognitive impairment,” Neurobiology of Aging, vol. 33, no. 2, pp. 425. e19–425. e27, 2012. View at: Publisher Site | Google Scholar
  14. K. W. Barañano and A. L. Hartman, “The ketogenic diet: uses in epilepsy and other neurologic illnesses,” Current Treatment Options in Neurology, vol. 10, no. 6, pp. 410–419, 2008. View at: Publisher Site | Google Scholar
  15. P. G. Sullivan, N. A. Rippy, K. Dorenbos, R. C. Concepcion, A. K. Agarwal, and J. M. Rho, “The ketogenic diet increases mitochondrial uncoupling protein levels and activity,” Annals of Neurology, vol. 55, no. 4, pp. 576–580, 2004. View at: Publisher Site | Google Scholar
  16. E. C. Westman, J. Mavropoulos, W. S. Yancy Jr., and J. S. Volek, “A review of low-carbohydrate ketogenic diets,” Current Atherosclerosis Reports, vol. 5, no. 6, pp. 476–483, 2003. View at: Publisher Site | Google Scholar
  17. K. M. Maruschak, Impact of a Low-Carbohydrate, High-Fat Modified Ketogenic Diet on Anthropometrics, Biochemical Values, and Gastrointestinal Symptoms in Adult Patients with Epilepsy, Rush University, Chicago, IL, USA, 2016.
  18. S. R. Send, The Impact of a Low-Carbohydrate, High-Fat Modified Ketogenic Diet on Seizure Severity, Seizure Frequency, and Quality of Life in Adult Patients with Epilepsy, Rush University, Chicago, IL, USA, 2016.
  19. C. Dudick, “Carb”(not “Keto”) is a Four Letter Word, 2016.
  20. M. Schmidt, N. Pfetzer, M. Schwab, I. Strauss, and U. Kämmerer, “Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: a pilot trial,” Nutrition and Metabolism, vol. 8, no. 1, p. 54, 2011. View at: Publisher Site | Google Scholar
  21. D. K. Layman and J. I. Baum, “Dietary protein impact on glycemic control during weight loss,” Journal of Nutrition, vol. 134, no. 4, pp. 968S–973S, 2004. View at: Publisher Site | Google Scholar
  22. C. Remesy, P. Fafournoux, and C. Demigne, “Control of hepatic utilization of serine, glycine and threonine in fed and starved rats,” Journal of Nutrition, vol. 113, no. 1, pp. 28–39, 1983. View at: Publisher Site | Google Scholar
  23. N. J. Krilanovich, “Benefits of ketogenic diets,” American Journal of Clinical Nutrition, vol. 85, no. 1, pp. 238-239, 2007. View at: Publisher Site | Google Scholar
  24. D. W. Kim, H. C. Kang, J. C. Park, and H. D. Kim, “Benefits of the nonfasting ketogenic diet compared with the initial fasting ketogenic diet,” Pediatrics, vol. 114, no. 6, pp. 1627–1630, 2004. View at: Publisher Site | Google Scholar
  25. R. L. Veech, “The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism,” Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 70, no. 3, pp. 309–319, 2004. View at: Publisher Site | Google Scholar
  26. J. D. McGarry, “Disordered metabolism in diabetes: have we underemphasized the fat component?” Journal of Cellular Biochemistry, vol. 55, no. S1994A, pp. 29–38, 1994. View at: Publisher Site | Google Scholar
  27. J. C. Newman and E. Verdin, “Ketone bodies as signaling metabolites,” Trends in Endocrinology and Metabolism, vol. 25, no. 1, pp. 42–52, 2014. View at: Publisher Site | Google Scholar
  28. O. Owen, G. Reichard Jr., H. Markus, G. Boden, M. Mozzoli, and C. Shuman, “Rapid intravenous sodium acetoacetate infusion in man metabolic and kinetic responses,” Journal of Clinical Investigation, vol. 52, no. 10, pp. 2606–2616, 1973. View at: Publisher Site | Google Scholar
  29. E. O. Balasse and F. Féry, “Ketone body production and disposal: effects of fasting, diabetes, and exercise,” Diabetes/Metabolism Reviews, vol. 5, no. 3, pp. 247–270, 1989. View at: Publisher Site | Google Scholar
  30. R. Wilson and W. Reeves, “Neutrophil phagocytosis and killing in insulin-dependent diabetes,” Clinical and Experimental Immunology, vol. 63, no. 2, p. 478, 1986. View at: Google Scholar
  31. M. Brownlee, H. Vlassara, A. Kooney, P. Ulrich, and A. Cerami, “Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking,” Science, vol. 232, no. 4758, pp. 1629–1632, 1986. View at: Publisher Site | Google Scholar
  32. N. Ahmed, “Advanced glycation endproducts—role in pathology of diabetic complications,” Diabetes Research and Clinical Practice, vol. 67, no. 1, pp. 3–21, 2005. View at: Publisher Site | Google Scholar
  33. P. Marceau, S. Biron, F. S. Hould et al., “Liver pathology and the metabolic syndrome X in severe obesity,” Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 5, pp. 1513–1517, 1999. View at: Publisher Site | Google Scholar
  34. M. Y. Donath and S. E. Shoelson, “Type 2 diabetes as an inflammatory disease,” Nature Reviews Immunology, vol. 11, no. 2, pp. 98–107, 2011. View at: Publisher Site | Google Scholar
  35. K. Moley, M. Y. Chi, C. Knudson, S. Korsmeyer, and M. Mueckler, “Hyperglycemia induces apoptosis in pre-implantation embryos through cell death effector pathways,” Nature Medicine, vol. 4, no. 12, pp. 1421–1424, 1998. View at: Publisher Site | Google Scholar
  36. S. P. Hays, E. B. Smith, and A. L. Sunehag, “Hyperglycemia is a risk factor for early death and morbidity in extremely low birth-weight infants,” Pediatrics, vol. 118, no. 5, pp. 1811–1818, 2006. View at: Publisher Site | Google Scholar
  37. H. Vlassara, “Advanced glycation end-products and atherosclerosis,” Annals of Medicine, vol. 28, no. 5, pp. 419–426, 1996. View at: Publisher Site | Google Scholar
  38. H. Yki-Jarvinen, “Glucose Toxicity,” Endocrine Reviews, vol. 13, no. 3, pp. 415–431, 1992. View at: Publisher Site | Google Scholar
  39. L. L. Madison, D. Mebane, R. H. Unger, and A. Lochner, “The hypoglycemic action of ketones. II. Evidence for a stimulatory feedback of ketones on the pancreatic beta cells,” Journal of Clinical Investigation, vol. 43, no. 3, pp. 408–415, 1964. View at: Publisher Site | Google Scholar
  40. A. Baron, G. Brechtel, and S. Edelman, “Effects of free fatty acids and ketone bodies on in vivo non-insulin-mediated glucose utilization and production in humans,” Metabolism, vol. 38, no. 11, pp. 1056–1061, 1989. View at: Publisher Site | Google Scholar
  41. T. A. Hussain, T. C. Mathew, A. A. Dashti, S. Asfar, N. Al-Zaid, and H. M. Dashti, “Effect of low-calorie versus low-carbohydrate ketogenic diet in type 2 diabetes,” Nutrition, vol. 28, no. 10, pp. 1016–1021, 2012. View at: Publisher Site | Google Scholar
  42. T. D. Noakes, “Low-carbohydrate and high-fat intake can manage obesity and associated conditions: occasional survey,” South African Medical Journal, vol. 103, no. 11, pp. 826–830, 2013. View at: Publisher Site | Google Scholar
  43. J. Ratliff, G. Mutungi, M. J. Puglisi, J. S. Volek, and M. L. Fernandez, “Carbohydrate restriction (with or without additional dietary cholesterol provided by eggs) reduces insulin resistance and plasma leptin without modifying appetite hormones in adult men,” Nutrition Research, vol. 29, no. 4, pp. 262–268, 2009. View at: Publisher Site | Google Scholar
  44. J. S. Volek, M. J. Sharman, D. M. Love, N. G. Avery, T. P. Scheett, and W. J. Kraemer, “Body composition and hormonal responses to a carbohydrate-restricted diet,” Metabolism, vol. 51, no. 7, pp. 864–870, 2002. View at: Publisher Site | Google Scholar
  45. C. A. Major, M. J. Henry, M. de Veciana, and M. A. Morgan, “The effects of carbohydrate restriction in patients with diet-controlled gestational diabetes,” Obstetrics and Gynecology, vol. 91, no. 4, pp. 600–604, 1998. View at: Publisher Site | Google Scholar
  46. A. Accurso, R. K. Bernstein, A. Dahlqvist et al., “Dietary carbohydrate restriction in type 2 diabetes mellitus and metabolic syndrome: time for a critical appraisal,” Nutrition and Metabolism, vol. 5, no. 1, p. 9, 2008. View at: Publisher Site | Google Scholar
  47. R. D. Feinman, W. K. Pogozelski, A. Astrup et al., “Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base,” Nutrition, vol. 31, no. 1, pp. 1–13, 2015. View at: Publisher Site | Google Scholar
  48. M. K. Badman, A. R. Kennedy, A. C. Adams, P. Pissios, and E. Maratos-Flier, “A very low carbohydrate ketogenic diet improves glucose tolerance in ob/ob mice independently of weight loss,” American Journal of Physiology-Endocrinology and Metabolism, vol. 297, no. 5, pp. E1197–E1204, 2009. View at: Publisher Site | Google Scholar
  49. K. Xu, X. Sun, B. O. Eroku, C. P. Tsipis, M. A. Puchowicz, and J. C. LaManna, “Diet-induced ketosis improves cognitive performance in aged rats,” in Advances in Experimental Medicine and Biology, pp. 71–75, Springer, Berlin, Germany, 2010. View at: Google Scholar
  50. K. D. Ballard, E. E. Quann, B. R. Kupchak et al., “Dietary carbohydrate restriction improves insulin sensitivity, blood pressure, microvascular function, and cellular adhesion markers in individuals taking statins,” Nutrition Research, vol. 33, no. 11, pp. 905–912, 2013. View at: Publisher Site | Google Scholar
  51. R. A. Hawkins, A. M. Mans, and D. W. Davis, “Regional ketone body utilization by rat brain in starvation and diabetes,” American Journal of Physiology-Endocrinology and Metabolism, vol. 250, no. 2, pp. E169–E178, 1986. View at: Publisher Site | Google Scholar
  52. T. N. Seyfried and P. Mukherjee, “Targeting energy metabolism in brain cancer: review and hypothesis,” Nutrition and Metabolism, vol. 2, no. 1, p. 30, 2005. View at: Publisher Site | Google Scholar
  53. L. Laffel, “Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes,” Diabetes/Metabolism Research and Reviews, vol. 15, no. 6, pp. 412–426, 1999. View at: Publisher Site | Google Scholar
  54. H. Krebs, “The regulation of the release of ketone bodies by the liver,” Advances in Enzyme Regulation, vol. 4, pp. 339–353, 1966. View at: Publisher Site | Google Scholar
  55. J. McGarry and D. Foster, “Regulation of hepatic fatty acid oxidation and ketone body production,” Annual Review of Biochemistry, vol. 49, no. 1, pp. 395–420, 1980. View at: Publisher Site | Google Scholar
  56. M. T. Newport, T. B. VanItallie, Y. Kashiwaya, M. T. King, and R. L. Veech, “A new way to produce hyperketonemia: use of ketone ester in a case of Alzheimer’s disease,” Alzheimer’s and Dementia, vol. 11, no. 1, pp. 99–103, 2015. View at: Publisher Site | Google Scholar
  57. E. C. Westman, R. D. Feinman, J. C. Mavropoulos et al., “Low-carbohydrate nutrition and metabolism,” American Journal of Clinical Nutrition, vol. 86, no. 2, pp. 276–284, 2007. View at: Publisher Site | Google Scholar
  58. C. Harvey, What is Nutritional Ketosis? 2015.
  59. I. F. Kodde, J. van der Stok, R. T. Smolenski, and J. W. de Jong, “Metabolic and genetic regulation of cardiac energy substrate preference,” Comparative Biochemistry and Physiology Part A: Molecular and Integrative Physiology, vol. 146, no. 1, pp. 26–39, 2007. View at: Publisher Site | Google Scholar
  60. B. Plecko, S. Stoeckler-Ipsiroglu, E. Schober et al., “Oral β-hydroxybutyrate supplementation in two patients with hyperinsulinemic hypoglycemia: monitoring of β-hydroxybutyrate levels in blood and cerebrospinal fluid, and in the brain by in vivo magnetic resonance spectroscopy,” Pediatric Research, vol. 52, no. 2, pp. 301–306, 2002. View at: Publisher Site | Google Scholar
  61. H. White and B. Venkatesh, “Clinical review: ketones and brain injury,” Critical Care, vol. 15, no. 2, p. 219, 2011. View at: Publisher Site | Google Scholar
  62. E. P. Vining, “Clinical efficacy of the ketogenic diet,” Epilepsy Research, vol. 37, no. 3, pp. 181–190, 1999. View at: Publisher Site | Google Scholar
  63. E. H. Kossoff, B. A. Zupec-Kania, and J. M. Rho, “Ketogenic diets: an update for child neurologists,” Journal of Child Neurology, vol. 24, no. 8, pp. 979–988, 2009. View at: Publisher Site | Google Scholar
  64. G. F. Cahill Jr., “Fuel metabolism in starvation,” Annual Review of Nutrition, vol. 26, no. 1, pp. 1–22, 2006. View at: Publisher Site | Google Scholar
  65. M. Gasior, M. A. Rogawski, and A. L. Hartman, “Neuroprotective and disease-modifying effects of the ketogenic diet,” Behavioural Pharmacology, vol. 17, no. 5-6, pp. 431–439, 2006. View at: Publisher Site | Google Scholar
  66. R. de Oliveira Caminhotto and F. B. Lima, “Low carbohydrate high fat diets: when models do not match reality,” Archives of Endocrinology and Metabolism, vol. 60, no. 4, pp. 405-406, 2016. View at: Publisher Site | Google Scholar
  67. M. G. Abdelwahab, S. H. Lee, D. O’Neill et al., “Ketones prevent oxidative impairment of hippocampal synaptic integrity through K ATP channels,” PLoS One, vol. 10, no. 4, Article ID e0119316, 2015. View at: Publisher Site | Google Scholar
  68. J. X. Yin, M. Maalouf, P. Han et al., “Ketones block amyloid entry and improve cognition in an Alzheimer’s model,” Neurobiology of Aging, vol. 39, pp. 25–37, 2016. View at: Publisher Site | Google Scholar
  69. J. Zhang, Q. Cao, S. Li et al., “3-Hydroxybutyrate methyl ester as a potential drug against Alzheimer’s disease via mitochondria protection mechanism,” Biomaterials, vol. 34, no. 30, pp. 7552–7562, 2013. View at: Publisher Site | Google Scholar
  70. L. Siegel, N. I. Robin, and L. J. McDonald, “New approach to determination of total ketone bodies in serum,” Clinical Chemistry, vol. 23, no. 1, pp. 46–49, 1977. View at: Google Scholar
  71. D. J. Angus, M. Hargreaves, J. Dancey, and M. A. Febbraio, “Effect of carbohydrate or carbohydrate plus medium-chain triglyceride ingestion on cycling time trial performance,” Journal of Applied Physiology, vol. 88, no. 1, pp. 113–119, 2000. View at: Publisher Site | Google Scholar
  72. L. Misell, N. Lagomarcino, V. Schuster, and M. Kern, “Chronic medium-chain triacylglycerol consumption and endurance performance in trained runners,” Journal of Sports Medicine and Physical Fitness, vol. 41, no. 2, p. 210, 2001. View at: Google Scholar
  73. V. Ööpik, S. Timpmann, L. Medijainen, and H. Lemberg, “Effects of daily medium-chain triglyceride ingestion on energy metabolism and endurance performance capacity in well-trained runners,” Nutrition Research, vol. 21, no. 8, pp. 1125–1135, 2001. View at: Publisher Site | Google Scholar
  74. Y. M. C. Liu, “Medium-chain triglyceride (MCT) ketogenic therapy,” Epilepsia, vol. 49, no. s8, pp. 33–36, 2008. View at: Publisher Site | Google Scholar
  75. A. E. Jeukendrup, W. Saris, P. Schrauwen, F. Brouns, and A. Wagenmakers, “Metabolic availability of medium-chain triglycerides coingested with carbohydrates during prolonged exercise,” Journal of Applied Physiology, vol. 79, no. 3, pp. 756–762, 1995. View at: Publisher Site | Google Scholar
  76. A. Poff, C. Ari, P. Arnold, T. Seyfried, and D. D’Agostino, “Ketone supplementation decreases tumor cell viability and prolongs survival of mice with metastatic cancer,” International Journal of Cancer, vol. 135, no. 7, pp. 1711–1720, 2014. View at: Publisher Site | Google Scholar
  77. Y. H. Youm, K. Y. Nguyen, R. W. Grant et al., “The ketone metabolite [beta]-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease,” Nature Medicine, vol. 21, no. 3, pp. 263–269, 2015. View at: Publisher Site | Google Scholar
  78. D. P. D'Agostino, R. Pilla, H. E. Held et al., “Therapeutic ketosis with ketone ester delays central nervous system oxygen toxicity seizures in rats,” American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, vol. 304, no. 10, pp. R829–R836, 2013. View at: Publisher Site | Google Scholar
  79. L. C. Gormsen, M. Svart, H. H. Thomsen et al., “Ketone body infusion with 3-hydroxybutyrate reduces myocardial glucose uptake and increases blood flow in humans: a positron emission tomography study,” Journal of the American Heart Association, vol. 6, no. 3, p. e005066, 2017. View at: Publisher Site | Google Scholar
  80. S. T. Henderson, J. L. Vogel, L. J. Barr, F. Garvin, J. J. Jones, and L. C. Costantini, “Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled, multicenter trial,” Nutrition and Metabolism, vol. 6, no. 1, p. 31, 2009. View at: Publisher Site | Google Scholar
  81. E. Arnaiz, V. Jelic, O. Almkvist et al., “Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment,” Neuroreport, vol. 12, no. 4, pp. 851–855, 2001. View at: Publisher Site | Google Scholar
  82. C. X. Gong, F. Liu, and K. Iqbal, “Impaired brain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O-GlcNAcylation,” Journal of Alzheimer’s Disease, vol. 9, no. 1, pp. 1–12, 2006. View at: Publisher Site | Google Scholar
  83. C. Messier, “Impact of impaired glucose tolerance and type 2 diabetes on cognitive aging,” Neurobiology of Aging, vol. 26, no. 1, pp. 26–30, 2005. View at: Publisher Site | Google Scholar
  84. S. T. Henderson, “Ketone bodies as a therapeutic for Alzheimer’s disease,” Neurotherapeutics, vol. 5, no. 3, pp. 470–480, 2008. View at: Publisher Site | Google Scholar
  85. T. B. VanItallie and T. H. Nufert, “Ketones: metabolism’s ugly duckling,” Nutrition Reviews, vol. 61, no. 10, pp. 327–341, 2003. View at: Publisher Site | Google Scholar
  86. M. Maalouf, P. G. Sullivan, L. Davis, D. Y. Kim, and J. M. Rho, “Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation,” Neuroscience, vol. 145, no. 1, pp. 256–264, 2007. View at: Publisher Site | Google Scholar
  87. C. B. Henderson, F. M. Filloux, S. C. Alder, J. L. Lyon, and D. A. Caplin, “Efficacy of the ketogenic diet as a treatment option for epilepsy: meta-analysis,” Journal of Child Neurology, vol. 21, no. 3, pp. 193–198, 2006. View at: Publisher Site | Google Scholar
  88. J. Sirven, B. Whedon, D. Caplan et al., “The ketogenic diet for intractable epilepsy in adults: preliminary results,” Epilepsia, vol. 40, no. 12, pp. 1721–1726, 1999. View at: Publisher Site | Google Scholar
  89. M. A. McNally and A. L. Hartman, “Ketone bodies in epilepsy,” Journal of Neurochemistry, vol. 121, no. 1, pp. 28–35, 2012. View at: Publisher Site | Google Scholar
  90. A. J. Murray, N. S. Knight, M. A. Cole et al., “Novel ketone diet enhances physical and cognitive performance,” Federation of American Societies for Experimental Biology Journal, vol. 30, no. 12, pp. 4021–4032, 2016. View at: Publisher Site | Google Scholar
  91. P. J. Pinckaers, T. A. Churchward-Venne, D. Bailey, and L. J. van Loon, “Ketone bodies and exercise performance: the next magic bullet or merely hype?” Sports Medicine, vol. 47, no. 3, pp. 383–391, 2017. View at: Publisher Site | Google Scholar
  92. T. Larsen and N. I. Nielsen, “Fluorometric determination of β-hydroxybutyrate in milk and blood plasma,” Journal of Dairy Science, vol. 88, no. 6, pp. 2004–2009, 2005. View at: Publisher Site | Google Scholar
  93. N. I. Nielsen, T. Larsen, M. Bjerring, and K. L. Ingvartsen, “Quarter health, milking interval, and sampling time during milking affect the concentration of milk constituents,” Journal of Dairy Science, vol. 88, no. 9, pp. 3186–3200, 2005. View at: Publisher Site | Google Scholar
  94. B. Stubbs, K. Willerton, S. Hiyama, K. Clarke, and P. Cox, Concomitant Meal Ingestion Alters Levels of Circulating Ketone Bodies following a Ketone Ester Drink, The Physiological Society, London, UK, 2015.
  95. K. Clarke, K. Tchabanenko, R. Pawlosky et al., “Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects,” Regulatory Toxicology and Pharmacology, vol. 63, no. 3, pp. 401–408, 2012. View at: Publisher Site | Google Scholar
  96. K. Clarke, K. Tchabanenko, R. Pawlosky et al., “Oral 28-day and developmental toxicity studies of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate,” Regulatory Toxicology and Pharmacology, vol. 63, no. 2, pp. 196–208, 2012. View at: Publisher Site | Google Scholar
  97. J. L. Van Hove, S. Grünewald, J. Jaeken et al., “D, L-3-hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase deficiency (MADD),” The Lancet, vol. 361, no. 9367, pp. 1433–1435, 2003. View at: Publisher Site | Google Scholar
  98. H. Endo, M. Niioka, N. Kobayashi, M. Tanaka, and T. Watanabe, “Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis,” PLoS One, vol. 8, no. 5, Article ID e63388, 2013. View at: Publisher Site | Google Scholar
  99. K. M. Maslowski and C. R. Mackay, “Diet, gut microbiota and immune responses,” Nature Immunology, vol. 12, no. 1, pp. 5–9, 2011. View at: Publisher Site | Google Scholar
  100. K. M. Tuohy, L. Conterno, M. Gasperotti, and R. Viola, “Up-regulating the human intestinal microbiome using whole plant foods, polyphenols, and/or fiber,” Journal of Agricultural and Food Chemistry, vol. 60, no. 36, pp. 8776–8782, 2012. View at: Publisher Site | Google Scholar
  101. J. M. Wong, R. De Souza, C. W. Kendall, A. Emam, and D. J. Jenkins, “Colonic health: fermentation and short chain fatty acids,” Journal of Clinical Gastroenterology, vol. 40, no. 3, pp. 235–243, 2006. View at: Publisher Site | Google Scholar
  102. M. Velasquez-Manoff, “Gut microbiome: the peacekeepers,” Nature, vol. 518, no. 7540, pp. S3–S11, 2015. View at: Publisher Site | Google Scholar
  103. O. Kanauchi, T. Iwanaga, K. Mitsuyama et al., “Butyrate from bacterial fermentation of germinated barley foodstuff preserves intestinal barrier function in experimental colitis in the rat model,” Journal of Gastroenterology and Hepatology, vol. 14, no. 9, pp. 880–888, 1999. View at: Publisher Site | Google Scholar
  104. H. Yadav, J. H. Lee, J. Lloyd, P. Walter, and S. G. Rane, “Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion,” Journal of Biological Chemistry, vol. 288, no. 35, pp. 25088–25097, 2013. View at: Publisher Site | Google Scholar
  105. H. J. Kim, P. Leeds, and D. M. Chuang, “The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain,” Journal of Neurochemistry, vol. 110, no. 4, pp. 1226–1240, 2009. View at: Publisher Site | Google Scholar
  106. Y. Yamawaki, M. Fuchikami, S. Morinobu, M. Segawa, T. Matsumoto, and S. Yamawaki, “Antidepressant-like effect of sodium butyrate (HDAC inhibitor) and its molecular mechanism of action in the rat hippocampus,” World Journal of Biological Psychiatry, vol. 13, no. 6, pp. 458–467, 2012. View at: Publisher Site | Google Scholar
  107. H. V. Lin, A. Frassetto, E. J. Kowalik Jr. et al., “Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms,” PLoS One, vol. 7, no. 4, Article ID e35240, 2012. View at: Publisher Site | Google Scholar
  108. Z. Gao, J. Yin, J. Zhang et al., “Butyrate improves insulin sensitivity and increases energy expenditure in mice,” Diabetes, vol. 58, no. 7, pp. 1509–1517, 2009. View at: Publisher Site | Google Scholar
  109. K. M. Tuohy, H. M. Probert, C. W. Smejkal, and G. R. Gibson, “Using probiotics and prebiotics to improve gut health,” Drug Discovery Today, vol. 8, no. 15, pp. 692–700, 2003. View at: Publisher Site | Google Scholar
  110. R. B. Canani, M. Di Costanzo, and L. Leone, “The epigenetic effects of butyrate: potential therapeutic implications for clinical practice,” Clinical Epigenetics, vol. 4, no. 1, p. 4, 2012. View at: Publisher Site | Google Scholar
  111. A. Alvaro, R. Sola, R. Rosales et al., “Gene expression analysis of a human enterocyte cell line reveals downregulation of cholesterol biosynthesis in response to short-chain fatty acids,” IUBMB Life, vol. 60, no. 11, pp. 757–764, 2008. View at: Publisher Site | Google Scholar
  112. J. W. Finley, J. B. Burrell, and P. G. Reeves, “Pinto bean consumption changes SCFA profiles in fecal fermentations, bacterial populations of the lower bowel, and lipid profiles in blood of humans,” Journal of Nutrition, vol. 137, no. 11, pp. 2391–2398, 2007. View at: Publisher Site | Google Scholar
  113. E. E. Canfora, J. W. Jocken, and E. E. Blaak, “Short-chain fatty acids in control of body weight and insulin sensitivity,” Nature Reviews Endocrinology, vol. 11, no. 10, pp. 577–591, 2015. View at: Publisher Site | Google Scholar
  114. J. Darzi, G. S. Frost, and M. D. Robertson, “Do SCFA have a role in appetite regulation?” Proceedings of the Nutrition Society, vol. 70, no. 1, pp. 119–128, 2011. View at: Publisher Site | Google Scholar
  115. A. Hague, B. Singh, and C. Paraskeva, “Butyrate acts as a survival factor for colonic epithelial cells: further fuel for the in vivo versus in vitro debate,” Gastroenterology, vol. 112, no. 3, pp. 1036–1040, 1997. View at: Publisher Site | Google Scholar
  116. J. R. Davie, “Inhibition of histone deacetylase activity by butyrate,” Journal of Nutrition, vol. 133, no. 7, pp. 2485S–2493S, 2003. View at: Publisher Site | Google Scholar
  117. D. P. Stefanko, R. M. Barrett, A. R. Ly, G. K. Reolon, and M. A. Wood, “Modulation of long-term memory for object recognition via HDAC inhibition,” Proceedings of the National Academy of Sciences, vol. 106, no. 23, pp. 9447–9452, 2009. View at: Publisher Site | Google Scholar
  118. S. G. Gray, “Epigenetic treatment of neurological disease,” Epigenomics, vol. 3, no. 4, pp. 431–450, 2011. View at: Google Scholar
  119. J. Segain, D. R. De La Blétiere, A. Bourreille et al., “Butyrate inhibits inflammatory responses through NFkappa B inhibition: implications for Crohn’s disease,” Gut, vol. 47, no. 3, pp. 397–403, 2000. View at: Publisher Site | Google Scholar
  120. E. L. Vieira, A. J. Leonel, A. P. Sad et al., “Oral administration of sodium butyrate attenuates inflammation and mucosal lesion in experimental acute ulcerative colitis,” Journal of Nutritional Biochemistry, vol. 23, no. 5, pp. 430–436, 2012. View at: Publisher Site | Google Scholar
  121. A. Sabatino, R. Morera, R. Ciccocioppo et al., “Oral butyrate for mildly to moderately active Crohn's disease,” Alimentary Pharmacology and Therapeutics, vol. 22, no. 9, pp. 789–794, 2005. View at: Publisher Site | Google Scholar
  122. A. Kotunia, J. Wolinski, D. Laubitz et al., “Effect of sodium butyrate on the small intestine,” Journal of Physiology and Pharmacology, vol. 55, no. 2, pp. 59–68, 2004. View at: Google Scholar
  123. Y. Furusawa, Y. Obata, S. Fukuda et al., “Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells,” Nature, vol. 504, no. 7480, pp. 446–450, 2013. View at: Publisher Site | Google Scholar
  124. H. M. Hamer, D. Jonkers, K. Venema, S. Vanhoutvin, F. Troost, and R. J. Brummer, “Review article: the role of butyrate on colonic function,” Alimentary Pharmacology and Therapeutics, vol. 27, no. 2, pp. 104–119, 2008. View at: Publisher Site | Google Scholar
  125. D. F. MacFabe, N. E. Cain, F. Boon, K. P. Ossenkopp, and D. P. Cain, “Effects of the enteric bacterial metabolic product propionic acid on object-directed behavior, social behavior, cognition, and neuroinflammation in adolescent rats: relevance to autism spectrum disorder,” Behavioural Brain Research, vol. 217, no. 1, pp. 47–54, 2011. View at: Publisher Site | Google Scholar
  126. D. F. MacFabe, D. P. Cain, K. Rodriguez-Capote et al., “Neurobiological effects of intraventricular propionic acid in rats: possible role of short chain fatty acids on the pathogenesis and characteristics of autism spectrum disorders,” Behavioural Brain Research, vol. 176, no. 1, pp. 149–169, 2007. View at: Publisher Site | Google Scholar
  127. N. Kratsman, D. Getselter, and E. Elliott, “Sodium butyrate attenuates social behavior deficits and modifies the transcription of inhibitory/excitatory genes in the frontal cortex of an autism model,” Neuropharmacology, vol. 102, pp. 136–145, 2016. View at: Publisher Site | Google Scholar
  128. M. W. Bourassa, I. Alim, S. J. Bultman, and R. R. Ratan, “Butyrate, neuroepigenetics and the gut microbiome,” Physiological Reviews, vol. 81, pp. 1031–1064, 2001. View at: Google Scholar
  129. N. I. McNeil, J. Cummings, and W. James, “Short chain fatty acid absorption by the human large intestine,” Gut, vol. 19, no. 9, pp. 819–822, 1978. View at: Publisher Site | Google Scholar
  130. O. C. Velazquez, H. M. Lederer, and J. L. Rombeau, Butyrate and the Colonocyte. Dietary Fiber in Health and Disease, Springer, Berlin, Germany, 1997.
  131. G. Sandle, “Salt and water absorption in the human colon: a modern appraisal,” Gut, vol. 43, no. 2, pp. 294–299, 1998. View at: Publisher Site | Google Scholar
  132. R. Havenaar, “Intestinal health functions of colonic microbial metabolites: a review,” Beneficial Microbes, vol. 2, no. 2, pp. 103–114, 2011. View at: Publisher Site | Google Scholar
  133. R. B. Canani, G. Terrin, P. Cirillo et al., “Butyrate as an effective treatment of congenital chloride diarrhea,” Gastroenterology, vol. 127, no. 2, pp. 630–634, 2004. View at: Publisher Site | Google Scholar
  134. J. Butzner, R. Parmar, C. Bell, and V. Dalal, “Butyrate enema therapy stimulates mucosal repair in experimental colitis in the rat,” Gut, vol. 38, no. 4, pp. 568–573, 1996. View at: Publisher Site | Google Scholar
  135. H. Li, Z. Gao, J. Zhang et al., “Sodium butyrate stimulates expression of fibroblast growth factor 21 in liver by inhibition of histone deacetylase 3,” Diabetes, vol. 61, no. 4, pp. 797–806, 2012. View at: Publisher Site | Google Scholar
  136. X. Zhang, D. C. Yeung, M. Karpisek et al., “Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans,” Diabetes, vol. 57, no. 5, pp. 1246–1253, 2008. View at: Publisher Site | Google Scholar
  137. F. Hird and R. Symons, “The mechanism of ketone-body formation from butyrate in rat liver,” Biochemical Journal, vol. 84, no. 1, pp. 212–216, 1962. View at: Publisher Site | Google Scholar
  138. R. Linskens, X. Huijsdens, P. Savelkoul, C. Vandenbroucke-Grauls, and S. Meuwissen, “The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics,” Scandinavian Journal of Gastroenterology, vol. 36, no. 234, pp. 29–40, 2001. View at: Publisher Site | Google Scholar
  139. R. B. Sartor, “Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics,” Gastroenterology, vol. 126, no. 6, pp. 1620–1633, 2004. View at: Publisher Site | Google Scholar
  140. A. K. Taggart, J. Kero, X. Gan et al., “(D)-β-hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G,” Journal of Biological Chemistry, vol. 280, no. 29, pp. 26649–26652, 2005. View at: Publisher Site | Google Scholar
  141. B. Egan and D. P. D’Agostino, “Fueling performance: ketones enter the mix,” Cell Metabolism, vol. 24, no. 3, pp. 373–375, 2016. View at: Publisher Site | Google Scholar
  142. A. J. Murray and H. E. Montgomery, “How wasting is saving: Weight loss at altitude might result from an evolutionary adaptation,” Bioessays, vol. 36, pp. 721–729, 2014. View at: Google Scholar
  143. C. C. Blad, K. Ahmed, A. P. Ijzerman, and S. Offermanns, “Biological and pharmacological roles of HCA receptors,” Advances in Pharmacology, vol. 62, pp. 219–250, 2014. View at: Publisher Site | Google Scholar
  144. S. Offermanns and M. Schwaninger, “Nutritional or pharmacological activation of HCA 2 ameliorates neuroinflammation,” Trends in Molecular Medicine, vol. 21, no. 4, pp. 245–255, 2015. View at: Publisher Site | Google Scholar
  145. S. Offermanns, “Free fatty acid (FFA) and hydroxy carboxylic acid (HCA) receptors,” Annual Review of Pharmacology and Toxicology, vol. 54, no. 1, pp. 407–434, 2014. View at: Publisher Site | Google Scholar
  146. S. Offermanns, S. L. Colletti, T. W. Lovenberg, G. Semple, A. Wise, and A. P. Ijzerman, “International union of basic and clinical pharmacology. LXXXII: nomenclature and classification of hydroxy-carboxylic acid receptors (GPR81, GPR109A, and GPR109B),” Pharmacological Reviews, vol. 63, no. 2, pp. 269–290, 2011. View at: Publisher Site | Google Scholar
  147. J. B. Milder, L. P. Liang, and M. Patel, “Acute oxidative stress and systemic Nrf2 activation by the ketogenic diet,” Neurobiology of Disease, vol. 40, no. 1, pp. 238–244, 2010. View at: Publisher Site | Google Scholar
  148. M. Storoni and G. T. Plant, “The therapeutic potential of the ketogenic diet in treating progressive multiple sclerosis,” Multiple Sclerosis International, vol. 2015, Article ID 681289, 9 pages, 2015. View at: Publisher Site | Google Scholar
  149. M. Sandberg, J. Patil, B. D'angelo, S. G. Weber, and C. Mallard, “NRF2-regulation in brain health and disease: implication of cerebral inflammation,” Neuropharmacology, vol. 79, pp. 298–306, 2014. View at: Publisher Site | Google Scholar
  150. H. C. Huang, T. Nguyen, and C. B. Pickett, “Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription,” Journal of Biological Chemistry, vol. 277, no. 45, pp. 42769–42774, 2002. View at: Publisher Site | Google Scholar
  151. J. Vriend and R. J. Reiter, “The Keap1-Nrf2-antioxidant response element pathway: a review of its regulation by melatonin and the proteasome,” Molecular and Cellular Endocrinology, vol. 401, pp. 213–220, 2015. View at: Publisher Site | Google Scholar
  152. N. Wei, D. Yuan, H. B. He et al., “Saponins from Panax japonicas reduces myocardial infarction induced reactive oxygen species production and cardiomyocyte apoptosis via activation of the Nrf-2 pathway,” Advanced Materials Research, vol. 881–883, pp. 339–346, 2014. View at: Publisher Site | Google Scholar
  153. J. S. Lee and Y. J. Surh, “Nrf2 as a novel molecular target for chemoprevention,” Cancer Letters, vol. 224, no. 2, pp. 171–184, 2005. View at: Publisher Site | Google Scholar
  154. S. Braun, C. Hanselmann, M. G. Gassmann et al., “Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound,” Molecular and Cellular Biology, vol. 22, no. 15, pp. 5492–5505, 2002. View at: Publisher Site | Google Scholar
  155. A. Y. Shih, S. Imbeault, V. Barakauskas et al., “Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo,” Journal of Biological Chemistry, vol. 280, no. 24, pp. 22925–22936, 2005. View at: Publisher Site | Google Scholar
  156. J. M. Lee, A. Y. Shih, T. H. Murphy, and J. A. Johnson, “NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons,” Journal of Biological Chemistry, vol. 278, no. 39, pp. 37948–37956, 2003. View at: Publisher Site | Google Scholar
  157. R. K. Thimmulappa, K. H. Mai, S. Srisuma, T. W. Kensler, M. Yamamoto, and S. Biswal, “Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray,” Cancer Research, vol. 62, no. 18, pp. 5196–5203, 2002. View at: Google Scholar
  158. R. K. Thimmulappa, C. Scollick, K. Traore et al., “Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide,” Biochemical and Biophysical Research Communications, vol. 351, no. 4, pp. 883–889, 2006. View at: Publisher Site | Google Scholar
  159. K. U. Tufekci, E. Civi Bayin, S. Genc, and K. Genc, “The Nrf2/ARE pathway: a promising target to counteract mitochondrial dysfunction in Parkinson’s disease,” Parkinson’s Disease, vol. 2011, p. 314082, 2011. View at: Publisher Site | Google Scholar
  160. X. He, H. Kan, L. Cai, and Q. Ma, “Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes,” Journal of Molecular and Cellular Cardiology, vol. 46, no. 1, pp. 47–58, 2009. View at: Publisher Site | Google Scholar
  161. Y. Tan, T. Ichikawa, J. Li et al., “Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress–induced insulin resistance in cardiac cells in vitro and in vivo,” Diabetes, vol. 60, no. 2, pp. 625–633, 2011. View at: Publisher Site | Google Scholar
  162. H. Zheng, S. A. Whitman, W. Wu et al., “Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy,” Diabetes, vol. 60, no. 11, pp. 3055–3066, 2011. View at: Publisher Site | Google Scholar
  163. J. M. Lee, J. Li, D. A. Johnson et al., “Nrf2, a multi-organ protector?” Federation of American Societies for Experimental Biology, vol. 19, no. 9, pp. 1061–1066, 2005. View at: Publisher Site | Google Scholar
  164. A. Neymotin, N. Y. Calingasan, E. Wille et al., “Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis,” Free Radical Biology and Medicine, vol. 51, no. 1, pp. 88–96, 2011. View at: Publisher Site | Google Scholar
  165. S. Yu, T. O. Khor, K. L. Cheung et al., “Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of TRAMP mice,” PLoS One, vol. 5, no. 1, Article ID e8579, 2010. View at: Publisher Site | Google Scholar
  166. H. Nagatomo, Y. Morimoto, A. Ogami et al., “Change of heme oxygenase-1 expression in lung injury induced by chrysotile asbestos in vivo and in vitro,” Inhalation Toxicology, vol. 19, no. 4, pp. 317–323, 2007. View at: Publisher Site | Google Scholar
  167. S. Suzuki, L. Toledo-Pereyra, F. Rodriguez, and D. Cejalvo, “Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury,” Transplantation, vol. 55, no. 6, pp. 1265–1272, 1993. View at: Publisher Site | Google Scholar
  168. P. Bowman, Amelioration of Ischemia/Reperfusion Injury During Resuscitation from Hemorrhage by Induction of Heme Oxygenase-1 (HO-1) in a Conscious Mouse Model of Uncontrolled Hemorrhage, DTIC Document, 2012.
  169. R. Hinkel, B. Petersen, M. Thormann et al., “hHO-1 overexpression in transgenic pigs is cardioprotective after acute myocardial ischemia and reperfsuion,” Circulation, vol. 120, no. 18, p. S1042, 2009. View at: Google Scholar
  170. T. Yoshida, M. Watanabe, D. T. Engelman et al., “Transgenic mice overexpressing glutathione peroxidase are resistant to myocardial ischemia reperfusion injury,” Journal of Molecular and Cellular Cardiology, vol. 28, no. 8, pp. 1759–1767, 1996. View at: Publisher Site | Google Scholar
  171. N. S. Dhalla, A. B. Elmoselhi, T. Hata, and N. Makino, “Status of myocardial antioxidants in ischemia–reperfusion injury,” Cardiovascular Research, vol. 47, no. 3, pp. 446–456, 2000. View at: Publisher Site | Google Scholar
  172. W. Dong, Y. Jia, X. Liu et al., “Sodium butyrate activates NRF2 to ameliorate diabetic nephropathy possibly via inhibition of HDAC,” Journal of Endocrinology, vol. 232, no. 1, pp. 71–83, 2017. View at: Publisher Site | Google Scholar
  173. X. Chen, W. Su, T. Wan et al., “Sodium butyrate regulates Th17/Treg cell balance to ameliorate uveitis via the Nrf2/HO-1 pathway,” Biochemical Pharmacology, vol. 142, pp. 111–119, 2017. View at: Publisher Site | Google Scholar
  174. X. Hu, K. Zhang, C. Xu, Z. Chen, and H. Jiang, “Anti-inflammatory effect of sodium butyrate preconditioning during myocardial ischemia/reperfusion,” Experimental and Therapeutic Medicine, vol. 8, no. 1, pp. 229–232, 2014. View at: Publisher Site | Google Scholar
  175. S. Yano and D. F. Tierney, “Butyrate increases catalase activity and protects rat pulmonary artery smooth muscle cells against hyperoxia,” Biochemical and Biophysical Research Communications, vol. 164, no. 3, pp. 1143–1148, 1989. View at: Publisher Site | Google Scholar
  176. M. E. Walsh, A. Bhattacharya, K. Sataranatarajan et al., “The histone deacetylase inhibitor butyrate improves metabolism and reduces muscle atrophy during aging,” Aging Cell, vol. 14, no. 6, pp. 957–970, 2015. View at: Publisher Site | Google Scholar

Copyright © 2018 Franco Cavaleri and Emran Bashar. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

15097 Views | 1561 Downloads | 9 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder
 Sign up for content alertsSign up